Nafamostat mesilate attenuates Postreperfusion Syndrome during liver transplantation.
Author(s): Ryu HG, Jung CW, Lee CS, Lee J
Affiliation(s): Department of Anesthesiology and Pain Medicine, Boramae Medical Center, Seoul, Korea.
Publication date & source: 2011-05, Am J Transplant., 11(5):977-83.
Publication type: Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Postreperfusion syndrome (PRS), an acute decrease in blood pressure after reperfusion of the liver graft, occurs frequently during liver transplantation surgery. We supposed that the activation of the kallikrein-kinin system leading to extensive systemic vasodilatation was a possible cause. The effect of pretreatment with nafamostat mesilate (NM), a broad spectrum serine protease inhibitor, on the occurrence of PRS was evaluated. Sixty-two adult liver recipients were randomized to receive an intravenous bolus of either 0.02 mg/kg of NM (NM group, n = 31) or an equal volume of normal saline (control group, n = 31) just before reperfusion of the liver graft. Occurrence of PRS and intraoperative use of vasoactive drugs were compared between the two groups. Postoperative recovery was also compared. PRS was significantly less frequent (48% vs. 81%, p = 0.016) requiring less vasopressors in the NM group compared to the control group. The NM group also showed faster recovery of the mean arterial pressure. Perioperative laboratory values were similar between the two groups. Pretreatment with 0.02 mg/kg of NM immediately before reperfusion decreases the frequency of PRS and vasopressor requirements during the reperfusion period in liver transplantation. (c)2011 The Authors Journal compilation(c)2011 The American Society of Transplantation and the American Society of Transplant Surgeons.